Skip to content

NRXP

NRX Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · US

$3.32
−2.06%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
+35.0%
EBIT
-40.3%
EPS
+68.1%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
+2404.0%
EBITDA
-22.2%
EPS
-2.2%

Three-year CAGR

Revenue
EBITDA
-15.7%
EBIT
+17.7%
Net income
-13.9%
EPS
+43.9%
Free cash flow
-32.7%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026